| LBCTR2020104622 | BO40336 | ALINA | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASEPOSITIVE NONSMALL CELL LUNG CANCER | Interventional | Other | 12/10/2020 |
| LBCTR2020073458 | MEQ00063 | A Phase III, open-label, study to describe the immunogenicity and safety of MenACYW conjugate vaccine in potential pilgrims ≥ 56 years of age in Turkey and Lebanon. | A Phase III, open-label, study to describe the immunogenicity and safety of MenACYW conjugate vaccine in potential pilgrims ≥ 56 years of age in Turkey and Lebanon. | Interventional | Other | 30/07/2020 |
| LBCTR2024015502 | WO43571 | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGOTAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGOTAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER | Interventional | Recruiting | 29/01/2024 |
| LBCTR2020033438 | MO39171 | A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL) | A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL) | Interventional | Complete | 22/03/2020 |
| LBCTR2021114915 | WA40404 | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | Interventional | Pending | 05/11/2021 |
| LBCTR2023025267 | CABL001J12302 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) | A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | Interventional | Suspended | 27/01/2023 |
| LBCTR2020124689 | CA209-7DJ/BIO-2019-0447 | A pilot study of Nivolumab with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma. | A pilot study of Nivolumab with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma. | Interventional | Pending | 28/01/2021 |
| LBCTR2022095114 | CLEE011A2412B | Roll-over Study to Allow Continued Access to Ribociclib | A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study | Interventional | Complete | 17/08/2022 |
| LBCTR2020074518 | OPERA2020 | A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma | A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma | Observational | Recruiting | 10/07/2020 |
| LBCTR2021024523 | GC1801 | Phase 3 study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia | A prospective, multicenter, open-label, single-arm study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia requiring either ondemand treatment for acute bleeding or surgical prophylaxis | Interventional | Pending | 14/07/2020 |